EUVIMEDEUVIMED entdecken
Open Access

Ki-67 Evaluation for Clinical Decision in Metastatic Lung Carcinoids: A Proof of Concept

Giuseppe Pelosi iD, Federica Massa, Gaia Gatti, Luisella Righi, Marco Volante, Nadia Birocco, Patrick Maisonneuve, Angelica Sonzogni, Sergio Harari, Adriana Albini, Mauro Papotti

Clinical Pathology · 2019-01 · 12

DOI: 10.1177/2632010x19829259 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pathology, online erschienen am 19.02.2019. Verfasst von Giuseppe Pelosi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: associazione italiana per la ricerca sul cancro.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Accrual of metastatic pulmonary carcinoid patients for therapy is usually relied on clinical and histologic characterization, with no role for the proliferation activity as defined by Ki-67 labelling index (LI). A total of 14 carcinoid patients with tumour primaries (TP) and 19 corresponding tumour metastases (TM) were blindly reviewed by 2 different pathologists for necrosis, mitotic count, and Ki-67 LI. Ki-67 LI outperformed histologic subtyping, mitotic count, and necrosis with good to almost excellent (0.40-0.75) inter-observer agreement. About 10% cut-off Ki-67 LI predicted survival better than histology for TP and TM for both observers. The TM patients survived differently according to diverse treatments (somatostatin analogues [SSAs], analogues plus additional treatments except for platinum; platinum-based chemotherapy) in close correlation with 20% cut-off thresholds of Ki-67 LI, respectively. There was also a trend for an increase in Ki-67 LI in TM as compared with TP. This is the first proof of concept in which a clinical potential is preliminarily suggested for Ki-67 LI to better stratify pulmonary metastatic carcinoid patients for treatment according to a criterion of histology-independent biological aggressiveness.

Schlagwörter

Stichwörter der Autor:innen

Ki-67 labelling indexcarcinoidhistologymetastasistherapy

Autor:innen und Institutionen

  • Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy.
  • Inter-hospital Pathology Division, Science & Technology Park, IRCCS MultiMedica, Milan, Italy.
  • Department of Oncology, University of Turin and Pathology Unit, Molinette Hospital, City of Health and Science, Turin, Italy.
  • Department of Oncology, University of Turin and Pathology Unit, San Luigi Hospital, Turin, Italy.
  • Medical Oncology, Molinette Hospital, City of Health and Science, Turin, Italy.
  • Division of Epidemiology and Biostatistics, European Institute of Oncology (IEO), IRCCS, Milan, Italy.

ORCID-Profile: Giuseppe Pelosi

Förderung

  • associazione italiana per la ricerca sul cancro

Zitieren

APA

Pelosi, G., Massa, F., Gatti, G., Righi, L., Volante, M., Birocco, N., Maisonneuve, P., Sonzogni, A., Harari, S., Albini, A., & Papotti, M. (2019). Ki-67 Evaluation for Clinical Decision in Metastatic Lung Carcinoids: A Proof of Concept. Clinical Pathology, 12. https://doi.org/10.1177/2632010x19829259

Vancouver

Pelosi G, Massa F, Gatti G, Righi L, Volante M, Birocco N, et al. Ki-67 Evaluation for Clinical Decision in Metastatic Lung Carcinoids: A Proof of Concept. Clinical Pathology. 2019;12. doi:10.1177/2632010x19829259

BibTeX
@article{Pelosi2019,
  author = {Pelosi, Giuseppe and Massa, Federica and Gatti, Gaia and Righi, Luisella and Volante, Marco and Birocco, Nadia and Maisonneuve, Patrick and Sonzogni, Angelica and Harari, Sergio and Albini, Adriana and Papotti, Mauro},
  title = {Ki-67 Evaluation for Clinical Decision in Metastatic Lung Carcinoids: A Proof of Concept},
  journal = {Clinical Pathology},
  year = {2019},
  volume = {12},
  doi = {10.1177/2632010x19829259}
}
Kostenlos starten →